Annovis Bio, Inc. (NYSE:ANVS) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock (or pre-funded warrants) and accompanying warrants Closed: US$21M raised · US$1 a share · Warrants at US$1 for 60 months · Canaccord Genuity Dealers: Canaccord Genuity (lead) Buyers: Chairman of the Board ($5.00 million, approximately 24% of the offering) Insiders: The Chairman of the Board contributed $5.00 million, approximately 24% of the offering Use of proceeds: Fund operations through the pivotal Phase 3 AD data readout and continued clinical development of buntanetap in AD and PD | Nov 9, 2026 |
| Public offering of underwritten public offering Closed: US$10M in the latest tranche · US$1.9 a share · Warrants at US$2.5 for 66 months · Canaccord Genuity Dealers: Canaccord Genuity (lead) Use of proceeds: Primarily to advance buntanetap through the pivotal Phase 3 Alzheimer's disease trial | Apr 13, 2026 |
| Registered direct offering of shares of common stock Announced: about US$3.4M · US$2.05 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Buyers: Michael Hoffman; Dr. Maria Maccecchini Insiders: Participation of Chairman Michael Hoffman and CEO Dr. Maria Maccecchini Use of proceeds: Working capital and general corporate purposes | Oct 27, 2025 |
| Registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) Closed: US$6M raised · US$1.5 a share · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Working capital and general corporate purposes | Oct 15, 2025 |